🔹 Revenue: $14.65B (Est. $13.5B) 🟢; UP +10% YoY
🔹 Adj EPS: $0.78 (Est. $0.58) 🟢; UP +30% YoY
🔹 Operating Margin Expansion Driven by Cost Savings
🔹 On track to deliver $7.2B in net cost savings by 2027
FY25 Guidance (Updated):
🔹 Adj EPS: $2.90–$3.10 🟢 (Prior: $2.80–$3.00)
🔹 Revenue: $61B–$64B (Reaffirmed)
🔹 Adjusted SI&A Expense: $13.1B–$14.1B (Lowered)
🔹 Adjusted R&D Expense: $10.4B–$11.4B (Lowered)
🔹 Effective Tax Rate: ~13% (Prior: ~15%)
🔹 Includes ~$0.20 EPS impact from 3SBio deal (1-time charge)
Segment Revenue:
🔹 Biopharma: $14.31B; UP +10% YoY
🔹 Pfizer CentreOne: $328M; UP +18% YoY
🔹 Pfizer Ignite: $20M; UP +38% YoY
Product Highlights (YoY Op. Growth):
🟢 Comirnaty: +95% — U.S. market share and intl. deliveries
🟢 Paxlovid: +71% — U.S. pricing and rebate adjustments
🟢 Vyndaqel family: +21% — strong demand & diagnosis
🟢 Padcev: +38% — mUC share gains, new distribution
🟢 Eliquis: +6% — global demand offset by U.S. pricing headwinds
🟢 Abrysvo: +155% — strong U.S. maternal uptake
🟢 Lorbrena: +48% — increased 1L ALK+ NSCLC share
🔴 Ibrance: -8% — IRA pricing + generic headwinds
Other Update:
🔹 R&D Spend Q2: $2.48B; DOWN -8% YoY
🔹 SI&A Expense Q2: $3.42B; DOWN -8% YoY
🔹 Dividends Paid YTD: $4.9B
🔹 No share buybacks YTD; $3.3B remaining authorization
🔹 Adjusted Net Income: $4.43B; UP +30% YoY
🔸 CEO Commentary:
🔸 “Strong quarter of focused execution—driving R&D and commercial momentum.” — CEO Albert Bourla
🔸 “Raised EPS guidance shows confidence in operational performance.” — CFO David Dento
